Healthcare company Viatris closed its $415 million acquisition of Oyster Point Pharma and its $280 million acquisition of Famy Life Sciences.
The acquisitions will form Viatris Eye Care Division. Viatris first announced the moves Nov. 7, according to a Jan. 3 Viatris news release.
Viatris is looking for the new division to power a potential $1 billion in new sales by 2028.
"With this combination we are well on our way to expand our portfolio and commercial footprint and create a global eye care leader," Jeffry Nau, PhD, head of the Viatris Eye Care Division, said in the release. "We believe that a new leader in the space can meaningfully shape the future of eye care to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them."